BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

530057

VIVANZA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Vivanza Biosciences Limited Share Price Update

As of the latest trading session, Vivanza Biosciences Limited share price is currently at ₹ 2.22, which is down by ₹ -0.04 from its previous closing. Today, the stock has fluctuated between ₹ 2.21 and ₹ 2.32. Over the past year, Vivanza Biosciences Limited has achieved a return of -72.09 %. In the last month alone, the return has been 7.21 %. Read More...

Vivanza Biosciences Limited fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    8.88

  • P/E Ratio (TTM)

    -74.33

  • Beta

    0.16

  • Book Value / share

    1.23

  • Return on equity

    7.02%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    0.04

info icon alternate text

Vivanza Biosciences Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 0.76
Operating Expense 0.74
Net Profit 0.04
Net Profit Margin (%) 5.26
Earnings Per Share (EPS) 0.01
EBITDA 0.13
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 1.58
Operating Expense 1.58
Net Profit 0.01
Net Profit Margin (%) 0.63
Earnings Per Share (EPS) 0.00
EBITDA 0.09
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.43
Operating Expense 0.20
Net Profit 0.23
Net Profit Margin (%) 53.48
Earnings Per Share (EPS) 0.06
EBITDA 0.32
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 2.30
Operating Expense 2.53
Net Profit -0.38
Net Profit Margin (%) -16.52
Earnings Per Share (EPS) -0.09
EBITDA -0.17
Effective Tax Rate (%) -40.74
Particulars DEC 2023 (Values in Cr)
Revenue 3.37
Operating Expense 3.20
Net Profit 0.18
Net Profit Margin (%) 5.34
Earnings Per Share (EPS) 0.05
EBITDA 0.28
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 14.41
Operating Expense 14.04
Net Profit 0.32
Net Profit Margin (%) 2.22
Earnings Per Share (EPS) 0.08
EBITDA 0.85
Effective Tax Rate (%) 25.58
Particulars MAR 2023 (Values in Cr)
Revenue 14.21
Operating Expense 13.91
Net Profit 0.57
Net Profit Margin (%) 4.01
Earnings Per Share (EPS) 1.42
EBITDA 1.10
Effective Tax Rate (%) 17.39
Particulars MAR 2022 (Values in Cr)
Revenue 9.15
Operating Expense 9.52
Net Profit 0.46
Net Profit Margin (%) 5.02
Earnings Per Share (EPS) 1.16
EBITDA 0.88
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 9.22
Operating Expense 9.58
Net Profit 0.10
Net Profit Margin (%) 1.08
Earnings Per Share (EPS) 0.25
EBITDA 0.63
Effective Tax Rate (%) 33.33
Particulars MAR 2020 (Values in Cr)
Revenue 9.43
Operating Expense 10.17
Net Profit -0.20
Net Profit Margin (%) -2.12
Earnings Per Share (EPS) -0.51
EBITDA 0.24
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.16
ROE % 12.60
ROCE % 10.23
Total Debt to Total Equity 1.51
EBITDA Margin 4.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.02
ROE % 14.84
ROCE % 10.65
Total Debt to Total Equity 1.78
EBITDA Margin 6.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.73
ROE % 8.25
ROCE % 10.96
Total Debt to Total Equity 0.88
EBITDA Margin 7.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 7.90
ROE % 2.26
ROCE % 15.32
Total Debt to Total Equity 0.12
EBITDA Margin 6.07
Particulars MAR 2020 (Values in Cr)
Book Value / Share 7.71
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.29
EBITDA Margin 2.39
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.18
ROE % 7.02
ROCE % 8.98
Total Debt to Total Equity 1.08
EBITDA Margin 5.97
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.10
ROE % 13.57
ROCE % 11.56
Total Debt to Total Equity 1.33
EBITDA Margin 7.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 9.57
ROE % 11.50
ROCE % 14.13
Total Debt to Total Equity 0.64
EBITDA Margin 9.84
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.41
ROE % 2.75
ROCE % 16.25
Total Debt to Total Equity 0.05
EBITDA Margin 6.83
Particulars MAR 2020 (Values in Cr)
Book Value / Share 8.16
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.16
EBITDA Margin 2.55
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 19.50
Total Liabilities 19.50
Total Equity 4.63
Share Outstanding 40000000
Price to Book Ratio 5.75
Return on Assets (%) 2.80
Return on Capital (%) 5.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 22.47
Total Liabilities 22.47
Total Equity 4.09
Share Outstanding 40000000
Price to Book Ratio 17.09
Return on Assets (%) 2.66
Return on Capital (%) 4.95
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 15.56
Total Liabilities 15.56
Total Equity 3.49
Share Outstanding 4000000
Price to Book Ratio 19.71
Return on Assets (%) 2.13
Return on Capital (%) 3.7
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments -3.09
Total Assets 8.44
Total Liabilities 8.44
Total Equity 3.15
Share Outstanding 4000000
Price to Book Ratio 15.53
Return on Assets (%) 0.89
Return on Capital (%) 2.14
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments -2.77
Total Assets 12.35
Total Liabilities 12.35
Total Equity 3.08
Share Outstanding 4000000
Price to Book Ratio 0.00
Return on Assets (%) -1.66
Return on Capital (%) -5.93
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 16.87
Total Liabilities 16.87
Total Equity 4.71
Share Outstanding 40000000
Price to Book Ratio 5.75
Return on Assets (%) 1.88
Return on Capital (%) 3.98
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 20.44
Total Liabilities 20.44
Total Equity 4.39
Share Outstanding 40000000
Price to Book Ratio 17.09
Return on Assets (%) 2.78
Return on Capital (%) 5.19
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 14.20
Total Liabilities 14.20
Total Equity 3.82
Share Outstanding 4000000
Price to Book Ratio 19.71
Return on Assets (%) 3.26
Return on Capital (%) 5.62
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments -3.11
Total Assets 7.93
Total Liabilities 7.93
Total Equity 3.36
Share Outstanding 4000000
Price to Book Ratio 15.53
Return on Assets (%) 1.25
Return on Capital (%) 2.82
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments -2.81
Total Assets 12.27
Total Liabilities 12.27
Total Equity 3.26
Share Outstanding 4000000
Price to Book Ratio 0.00
Return on Assets (%) -1.65
Return on Capital (%) -5.92
Particulars MAR 2024 (Values in Cr)
Net Income 0.69
Cash from Operations 2.19
Cash from Investing -0.03
Cash from Financing -1.98
Net change in Cash 0.02
Free Cash Flow 2.23
Particulars MAR 2023 (Values in Cr)
Net Income 0.71
Cash from Operations -0.82
Cash from Investing 0.00
Cash from Financing 1.03
Net change in Cash 0.08
Free Cash Flow -0.82
Particulars MAR 2022 (Values in Cr)
Net Income 0.33
Cash from Operations 2.46
Cash from Investing 0.00
Cash from Financing -2.47
Net change in Cash -0.01
Free Cash Flow 2.46
Particulars MAR 2021 (Values in Cr)
Net Income 0.14
Cash from Operations -3.02
Cash from Investing -0.02
Cash from Financing 2.79
Net change in Cash -0.30
Free Cash Flow -3.00
Particulars MAR 2020 (Values in Cr)
Net Income -0.20
Cash from Operations 2.97
Cash from Investing 0.00
Cash from Financing -2.75
Net change in Cash 0.22
Free Cash Flow 2.97
Particulars MAR 2024 (Values in Cr)
Net Income 0.42
Cash from Operations 1.89
Cash from Investing -0.03
Cash from Financing -1.76
Net change in Cash -0.01
Free Cash Flow 1.93
Particulars MAR 2023 (Values in Cr)
Net Income 0.68
Cash from Operations 0.27
Cash from Investing 0.00
Cash from Financing -0.07
Net change in Cash 0.08
Free Cash Flow 0.27
Particulars MAR 2022 (Values in Cr)
Net Income 0.46
Cash from Operations -0.67
Cash from Investing 0.00
Cash from Financing 0.65
Net change in Cash -0.02
Free Cash Flow -0.67
Particulars MAR 2021 (Values in Cr)
Net Income 0.14
Cash from Operations -3.02
Cash from Investing -0.02
Cash from Financing 2.79
Net change in Cash -0.30
Free Cash Flow -3.00
Particulars MAR 2020 (Values in Cr)
Net Income -0.20
Cash from Operations 2.79
Cash from Investing 0.00
Cash from Financing -2.58
Net change in Cash 0.21
Free Cash Flow 2.79
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

Vivanza Biosciences Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2.23 -1.76 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 2.30
  • 26 Days 2.30
  • 10 Days 2.30
  • 50 Days 2.40
  • 12 Days 2.30
  • 100 Days 2.80
  • 20 Days 2.30
  • 200 Days 3.80
2.27 PIVOT

First Support

2.21

First Resistance

2.32

Second Support

2.16

Second Resistance

2.38

Third Support

2.10

Third Resistance

2.43

RSI

45.07

ADX

13.88

MACD

0.00

Williams % R

-64.52

Commodity Channel Index (CCI)

-1.22

Date

2025-04-30

Week

63394.00

Same Day

40426.00

Month

59489.00

1 Year

0.16

3 Year

-0.03

Over 1 Month

7.21%

down

Over 1 Year

-72.09%

down

Over 3 Months

-25.16%

down

Over 3 Years

-50.45%

down

Over 6 Months

-40.69%

down

Over 5 Years

12.27%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

Vivanza Biosciences Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
79.97%
Promoter Holdings
20.01%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Parth Hemant Parikh 7907622.0 (19.77%) Shareholding of Promoter and Promoter Group
Ashoka Metcast Limited 1539259.0 (3.85%) Public Shareholding
Prashant Tyagi 604509.0 (1.51%) Public Shareholding
Ammishi M Desai 555450.0 (1.39%) Public Shareholding
Hemant Amrish Parikh 100211.0 (0.25%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Vivanza Biosciences Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
24 Mar 2023 10.0 1.0 24 Mar 2023

Vivanza Biosciences Limited Share Price

Vivanza Biosciences Ltd (Previously known Ivee Injectaa Limited) was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992. Head quartered in Gujarat, India, the Company came into existence in April 2016 with the sole aim to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.
The Company is presently engaged in the business of Pharmaceutical Products and Pharma Products.

However Competition in the industry is continuously increasing. New technology is being adopted and steps are taken to improve the manufacturing capacity of the Company. Further, the Company has also set its vision in global market to supply and execute turnkey pharmaceutical units.

The company undertook an expansion-cum-diversification programme to increase its capacity from 18 lac pa to 54 lac pa. It also proposed to diversify into the manufacture of small volume parenterals with an installed capacity of 294 lac pa. It came out with a public issue of 21,70,000 equity shares of Rs 10 each for cash at par aggregating Rs 217 lac. It is one of the few companies which has facilities for both glass as well as plastic containers.

Due to recessionary trends which lead to difficult business conditions in the year 1999-2000, the parenteral industry suffered a setback. As a result of this, the name of the Company was changed from Ivee Injectaa Ltd. to Vivanza Biosciences Ltd in 2015.

The Company acquired 100% Equity Shares of Vivanza Lifesciences Private Limited and by virtue of the holding in Vivanza Lifesciences Private Limited it became Wholly Owned Subsidiary w.e.f. 17/06/2016.

Parent organization Indian Private
NSE symbol [-]
Founded 1982
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Vivanza Biosciences Ltd?

Answer Field

The share price of Vivanza Biosciences Ltd for NSE is ₹ 0.00 and for BSE is ₹ 2.23.

What is the Market Cap of Vivanza Biosciences Ltd?

Answer Field

The market cap of Vivanza Biosciences Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 8.90 Cr. as of now.

What is the 52 Week High and Low of Vivanza Biosciences Ltd?

Answer Field

The 52 Week High and Low of Vivanza Biosciences Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 8.23 and ₹ 1.90.

How to Buy Vivanza Biosciences Ltd share?

Answer Field

You can trade in Vivanza Biosciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Vivanza Biosciences Ltd?

Answer Field

The 1 year returns on the stock has been -72.09%.

What is the Current Share Price of Vivanza Biosciences Ltd?

Answer Field

Vivanza Biosciences Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 2.23 as on Apr 30 2025 03:19 PM.

What is the Market Cap of Vivanza Biosciences Ltd Share?

Answer Field

The market cap of Vivanza Biosciences Ltd for NSE ₹ 0.0 & for BSE ₹ 8.90 as on Apr 30 2025 03:19 PM.

What is the P/E Ratio of Vivanza Biosciences Ltd Share?

Answer Field

As on Apr 30 2025 03:19 PM the price-to-earnings (PE) ratio for Vivanza Biosciences Ltd share is -74.33.

What is the PB ratio of Vivanza Biosciences Ltd Share?

Answer Field

As on Apr 30 2025 03:19 PM, the price-to-book (PB) ratio for Vivanza Biosciences Ltd share is 1.23.

How to Buy Vivanza Biosciences Ltd Share?

Answer Field

You can trade in Vivanza Biosciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vivanza Biosciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Vivanza Biosciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vivanza Biosciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|